IPSC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Century Therapeutics Inc (IPSC) is not a strong buy for a beginner, long-term investor at this moment. The company's financial performance is weak, with revenue dropping to zero in the latest quarter. While there are positive developments in the cancer immunotherapy space, the stock's technical indicators and hedge fund selling trends do not suggest immediate upside potential. The options data also reflects low put-call ratios, indicating limited trading sentiment. For a long-term investor, it may be better to wait for more concrete financial improvements or stronger catalysts before investing.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 69.375, and moving averages are converging, showing no clear direction. The stock is trading near resistance levels (R1: 2.099, R2: 2.223), which may limit short-term upside.
Robust growth in cancer immunotherapy, with over 12 companies developing iPSC-derived NK cell drugs.
Century Therapeutics is actively working on new drugs, including CNTY-101, with preliminary results showing promise.
Hedge funds are selling the stock, with a 179.43% increase in selling activity over the last quarter.
Financial performance is weak, with revenue dropping to zero in Q3
No significant insider or congress trading activity to indicate confidence in the stock.
In Q3 2025, revenue dropped to 0 (-100% YoY). Net income improved slightly to -$34.42M (+10.24% YoY), and EPS increased to -0.4 (+8.11% YoY). Gross margin remained at 100%, but the lack of revenue is a major concern.
No recent analyst rating or price target changes are available for IPSC.
